NASDAQ$CRBU
Caribou Biosciences Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Caribou Biosciences reported financial results for the third quarter 2024 and reviewed recent pipeline progress.
Caribou Biosciences reported a net loss of $34.7 million for the third quarter of 2024, with licensing and collaboration revenue of $2.0 million. The company's cash, cash equivalents, and marketable securities totaled $281.0 million as of September 30, 2024, expected to fund operations into H2 2026.
- Advanced four clinical-stage programs for hematologic malignancies and autoimmune diseases, with multiple clinical data reports planned for 2025.
- Enrolled patients with LBCL (2L and after prior CD19-targeted therapies) with HLA matching strategy in CB-010 ANTLER Phase 1 trial; next data report planned for H1 2025.
- Continued dose escalation portion of the CB-011 CaMMouflage Phase 1 trial in r/r MM with higher lymphodepletion regimen following observations of efficacy; dose escalation data to be presented H1 2025.
- Cash, cash equivalents, and marketable securities expected to fund the current operating plan into H2 2026.
Headline financials
Revenue & EPS history
Caribou Biosciences · Revenue · Quarterly
$2.02M
Revenue by segment
Caribou Biosciences · $3.76M total across 1 segment · Q2 2023
- Licensing & collaboration$3.76M-10.6%100.0%
Forward guidance
Caribou Biosciences plans to present data from the ANTLER clinical trial, initiate the GALLOP Phase 1 clinical trial, present dose escalation data from the CaMMouflage Phase 1 clinical trial, and provide updates on dose escalation from the AMpLify Phase 1 clinical trial.
Tailwinds
- CB-010 ANTLER: Present data from both the additional 2L and prior CD19 relapsed LBCL patient cohorts in H1 2025.
- CB-010 ANTLER: Initiate a pivotal Phase 3 clinical trial in H2 2025 should data confirm the initial observation that partial HLA matching is associated with improved outcomes for patients.
- CB-010 GALLOP: Initiate the GALLOP Phase 1 clinical trial in adult patients with LN and ERL by year-end 2024.
- CB-011 CaMMouflage: Present dose escalation data from the ongoing CaMMouflage Phase 1 clinical trial in r/r MM in H1 2025.
- CB-012 AMpLify: Provide updates on dose escalation as the AMpLify Phase 1 clinical trial in r/r AML advances.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2024
-0.8%
Avg return
Earnings day
+0.9%
Avg return
5 days after
-5.2%
Avg return
30 days after
53%
10 / 19 earnings
Positive
+11.1%
Q2 2021
Best reaction
-32.3%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.1% | +4.1% | -1.5% | |
| Q4 2025 | +6.5% | +15.2% | +13.5% | |
| Q3 2025 | -12.1% | -17.3% | -20.8% | |
| Q1 2025 | +10.5% | +16.7% | +19.4% | |
| Q4 2024 | +0.1% | -8.6% | -22.2% | |
| Q3 2024 | +8.6% | +9.0% | -16.8% | |
| Q2 2024 | -3.1% | -0.8% | -6.4% | |
| Q1 2024 | -8.6% | -7.6% | -45.4% | |
| Q4 2023 | -32.3% | -27.6% | -41.4% | |
| Q3 2023 | -5.0% | -19.3% | +24.7% | |
| Q2 2023 | +5.2% | +5.8% | -12.0% | |
| Q1 2023 | +9.3% | -2.1% | +4.0% | |
| Q4 2022 | -11.8% | -11.4% | -9.9% | |
| Q3 2022 | +3.9% | +15.0% | +2.4% | |
| Q2 2022 | +10.1% | +17.3% | +40.7% | |
| Q1 2022 | -0.5% | +22.4% | +23.7% | |
| Q4 2021 | +2.6% | -5.6% | -16.1% | |
| Q3 2021 | -4.9% | -0.5% | -18.2% | |
| Q2 2021 | +11.1% | +12.3% | -17.3% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro